Abstract
Resistance to antiretroviral drugs is one of the major pitfalls of combined treatment of HIV infection. Thus, timely identification of drug resistant HIV strains and precise evaluation of the level of resistance to the different antiretroviral drugs are crucial in the management of treated patients. Phenotypic determination of antiretroviral drug resistance evaluates the ability of an HIV strain to replicate in the presence of drug(s). Thus, this assay (either conventional or recombinant) provides a direct estimate of drug susceptibility. However, it is relatively difficult to perform and requires dedicated facilities. Thus, its use is still restricted. Genotypic determination of drug resistance is based upon detection of specific mutations in HIV genes encoding target enzymes or receptors. The assay provides an indirect evidence of drug susceptibility. However, it is easy to perform and does not require dedicated facilities. Thus, it is widely utilized in clinical practice. Its major limitation concerns the complexity of results interpretation which still awaits a general consensus.
Keywords: HIV Resistance, Antiviral Drugs, Phenotypic
Current Drug Metabolism
Title: Assays for Determination of HIV Resistance to Antiviral Drugs
Volume: 5 Issue: 4
Author(s): Fausto Baldanti, Stefania Paolucci, Luca Dossena and Giuseppe Gerna
Affiliation:
Keywords: HIV Resistance, Antiviral Drugs, Phenotypic
Abstract: Resistance to antiretroviral drugs is one of the major pitfalls of combined treatment of HIV infection. Thus, timely identification of drug resistant HIV strains and precise evaluation of the level of resistance to the different antiretroviral drugs are crucial in the management of treated patients. Phenotypic determination of antiretroviral drug resistance evaluates the ability of an HIV strain to replicate in the presence of drug(s). Thus, this assay (either conventional or recombinant) provides a direct estimate of drug susceptibility. However, it is relatively difficult to perform and requires dedicated facilities. Thus, its use is still restricted. Genotypic determination of drug resistance is based upon detection of specific mutations in HIV genes encoding target enzymes or receptors. The assay provides an indirect evidence of drug susceptibility. However, it is easy to perform and does not require dedicated facilities. Thus, it is widely utilized in clinical practice. Its major limitation concerns the complexity of results interpretation which still awaits a general consensus.
Export Options
About this article
Cite this article as:
Baldanti Fausto, Paolucci Stefania, Dossena Luca and Gerna Giuseppe, Assays for Determination of HIV Resistance to Antiviral Drugs, Current Drug Metabolism 2004; 5 (4) . https://dx.doi.org/10.2174/1389200043335496
DOI https://dx.doi.org/10.2174/1389200043335496 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Bovine Basic Pancreatic Trypsin Inhibitor (Kunitz Inhibitor): A Milestone Protein
Current Protein & Peptide Science Presentation of Lipid Antigens by CD1 Glycoproteins
Current Pharmaceutical Design Medical Complications in Anorexia and Bulimia Nervosa
Endocrine, Metabolic & Immune Disorders - Drug Targets Modulation of Energy Intake and Expenditure Due to Habitual Physical Exercise
Current Pharmaceutical Design Lysosomal Rerouting of Hsp70 Trafficking as a Potential Immune Activating Tool for Targeting Melanoma
Current Pharmaceutical Design Assessment of a Novel Vitamin D<sub>3</sub> Formulation with Nanostructured Lipid Carriers for Transdermal Delivery
Current Drug Delivery New Insights into HLA-G and Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Lipid Alterations in the Earliest Clinically Recognizable Stage of Alzheimers Disease: Implication of the Role of Lipids in the Pathogenesis of Alzheimers Disease
Current Alzheimer Research Approaching Clinical Reality: Markers for Monitoring Systemic Inflammation and Sepsis
Current Molecular Medicine Chloroquine and Hydroxychloroquine as Inhibitors of Human Immunodeficiency Virus (HIV-1) Activity
Current Pharmaceutical Design ATP-Binding Cassette Efflux Transporters in Human Placenta
Current Pharmaceutical Biotechnology Aging and Systemic Lupus Erythematosus - Immunosenescence and Beyond
Current Aging Science Clinical Pharmacology of Systemic Analgesics in Neonates
Current Drug Therapy Glutamate Signaling in Synaptogenesis and NMDA Receptors as Potential Therapeutic Targets for Psychiatric Disorders
Current Molecular Medicine Ulcerative Colitis: Pathogenesis
Current Drug Targets Anesthetic Pharmacology and Perioperative Considerations for the End Stage Liver Disease Patient
Current Clinical Pharmacology Chondroitin Sulphate for the Treatment of Osteoarthritis
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Anti-HIV Drug Development: Structural Features and Limitations of Present Day Drugs and Future Challenges in the Successful HIV/AIDS Treatment
Current Pharmaceutical Design Plasma Pharmacokinetics of Antimicrobial Agents in Critically Ill Patients
Current Clinical Pharmacology Novel Agents in the Management of Lung Cancer
Current Medicinal Chemistry